154 related articles for article (PubMed ID: 38312227)
1. Differences in methylation profiles between long-term survivors and short-term survivors of IDH-wild-type glioblastoma.
van der Meulen M; Ramos RC; Voisin MR; Patil V; Wei Q; Singh O; Climans SA; Kalidindi N; Or R; Aldape K; Diamandis P; Munoz DG; Zadeh G; Mason WP
Neurooncol Adv; 2024; 6(1):vdae001. PubMed ID: 38312227
[TBL] [Abstract][Full Text] [Related]
2. Molecular features of glioblastomas in long-term survivors compared to short-term survivors-a matched-pair analysis.
Sommerlath VN; Buergy D; Etminan N; Brehmer S; Reuss D; Sarria GR; Guiot MC; Hänggi D; Wenz F; Petrecca K; Giordano FA
Radiat Oncol; 2022 Jan; 17(1):15. PubMed ID: 35073955
[TBL] [Abstract][Full Text] [Related]
3. Molecular profiling of long-term IDH-wildtype glioblastoma survivors.
Burgenske DM; Yang J; Decker PA; Kollmeyer TM; Kosel ML; Mladek AC; Caron AA; Vaubel RA; Gupta SK; Kitange GJ; Sicotte H; Youland RS; Remonde D; Voss JS; Fritcher EGB; Kolsky KL; Ida CM; Meyer FB; Lachance DH; Parney IJ; Kipp BR; Giannini C; Sulman EP; Jenkins RB; Eckel-Passow JE; Sarkaria JN
Neuro Oncol; 2019 Nov; 21(11):1458-1469. PubMed ID: 31346613
[TBL] [Abstract][Full Text] [Related]
4. Differential Predictors and Clinical Implications Associated With Long-Term Survivors in IDH Wildtype and Mutant Glioblastoma.
Jiang H; Yu K; Cui Y; Ren X; Li M; Zhang G; Yang C; Zhao X; Zhu Q; Lin S
Front Oncol; 2021; 11():632663. PubMed ID: 34055603
[TBL] [Abstract][Full Text] [Related]
5. DNA methylation profiles of long- and short-term glioblastoma survivors.
Shinawi T; Hill VK; Krex D; Schackert G; Gentle D; Morris MR; Wei W; Cruickshank G; Maher ER; Latif F
Epigenetics; 2013 Feb; 8(2):149-56. PubMed ID: 23291739
[TBL] [Abstract][Full Text] [Related]
6. IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients.
Amelot A; De Cremoux P; Quillien V; Polivka M; Adle-Biassette H; Lehmann-Che J; Françoise L; Carpentier AF; George B; Mandonnet E; Froelich S
PLoS One; 2015; 10(7):e0130596. PubMed ID: 26158269
[TBL] [Abstract][Full Text] [Related]
7. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M;
Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605
[TBL] [Abstract][Full Text] [Related]
8. LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients.
Mock A; Geisenberger C; Orlik C; Warta R; Schwager C; Jungk C; Dutruel C; Geiselhart L; Weichenhan D; Zucknick M; Nied AK; Friauf S; Exner J; Capper D; Hartmann C; Lahrmann B; Grabe N; Debus J; von Deimling A; Popanda O; Plass C; Unterberg A; Abdollahi A; Schmezer P; Herold-Mende C
Int J Cancer; 2016 Jul; 139(2):424-32. PubMed ID: 26934681
[TBL] [Abstract][Full Text] [Related]
9. Long-term survival in patients with IDH-wildtype glioblastoma: clinical and molecular characteristics.
Chehade G; Lawson TM; Lelotte J; Daoud L; Di Perri D; Whenham N; Duprez T; Tajeddine N; Tissir F; Raftopoulos C
Acta Neurochir (Wien); 2023 Apr; 165(4):1075-1085. PubMed ID: 36920664
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive molecular characterization of long-term glioblastoma survivors.
Xu H; Chen X; Sun Y; Hu X; Zhang X; Wang Y; Tang Q; Zhu Q; Song K; Chen H; Sheng X; Yao Y; Zhuang D; Chen L; Mao Y; Qin Z
Cancer Lett; 2024 May; 593():216938. PubMed ID: 38734160
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological and molecular landscape of 5-year IDH-wild-type glioblastoma survivors: A multicentric retrospective study.
Miele E; Anghileri E; Calatozzolo C; Lazzarini E; Patrizi S; Ciolfi A; Pedace L; Patanè M; Abballe L; Paterra R; Maddaloni L; Barresi S; Mastronuzzi A; Petruzzi A; Tramacere I; Farinotti M; Gurrieri L; Pirola E; Scarpelli M; Lombardi G; Villani V; Simonelli M; Merli R; Salmaggi A; Tartaglia M; Silvani A; DiMeco F; Calistri D; Lamperti E; Locatelli F; Indraccolo S; Pollo B
Cancer Lett; 2024 Apr; 588():216711. PubMed ID: 38423245
[TBL] [Abstract][Full Text] [Related]
12. Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival.
Michaelsen SR; Urup T; Olsen LR; Broholm H; Lassen U; Poulsen HS
J Neurooncol; 2018 May; 137(3):533-542. PubMed ID: 29305787
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of deeply phenotyped GBM cohorts of 'short-term' and 'long-term' survivors.
Biswas A; Salvucci M; Connor K; Düssmann H; Carberry S; Fichtner M; King E; Murphy B; O'Farrell AC; Cryan J; Beausang A; Heffernan J; Cremona M; Hennessy BT; Clerkin J; Sweeney KJ; MacNally S; Brett F; O'Halloran P; Bacon O; Furney S; Verreault M; Quissac E; Bielle F; Ahmed MH; Idbaih A; Leenstra S; Ntafoulis I; Fabro F; Lamfers M; Golebiewska A; Hertel F; Niclou SP; Yen RTC; Kremer A; Dilcan G; Lodi F; Arijs I; Lambrechts D; Purushothama MK; Kel A; Byrne AT; Prehn JHM
J Neurooncol; 2023 Jun; 163(2):327-338. PubMed ID: 37237151
[TBL] [Abstract][Full Text] [Related]
14. Long-term survivors of glioblastoma: Tumor molecular, clinical, and imaging findings.
Briceno N; Vera E; Komlodi-Pasztor E; Abdullaev Z; Choi A; Grajkowska E; Kunst T; Levine J; Lindsley M; Fernandez K; Reyes J; Boris L; Burton E; Panzer M; Polskin L; Penas-Prado M; Pillai T; Theeler BJ; Wu J; Wall K; Papanicolau-Sengos A; Quezado M; Smirniotopoulos J; Aldape K; Armstrong TS; Gilbert MR
Neurooncol Adv; 2024; 6(1):vdae019. PubMed ID: 38420614
[TBL] [Abstract][Full Text] [Related]
15.
Mittlmeier LM; Suchorska B; Ruf V; Holzgreve A; Brendel M; Herms J; Bartenstein P; Tonn JC; Unterrainer M; Albert NL
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34202726
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of
Lam K; Eldred BSC; Kevan B; Pianka S; Eldred BA; Zapanta Rinonos S; Yong WH; Liau LM; Nghiemphu PL; Cloughesy TF; Green RM; Lai A
Neurooncol Adv; 2022; 4(1):vdac030. PubMed ID: 35386566
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Factors Associated with Long-Term Survival in Patients with Glioblastoma.
Madhugiri VS; Moiyadi AV; Shetty P; Gupta T; Epari S; Jalali R; Subeikshanan V; Dutt A; Sasidharan GM; Roopesh Kumar VR; Shankar Ganesh CV; Ramesh AS; Sathia Prabhu A
World Neurosurg; 2021 May; 149():e758-e765. PubMed ID: 33540096
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide DNA methylation profiling identifies ALDH1A3 promoter methylation as a prognostic predictor in G-CIMP- primary glioblastoma.
Zhang W; Yan W; You G; Bao Z; Wang Y; Liu Y; You Y; Jiang T
Cancer Lett; 2013 Jan; 328(1):120-5. PubMed ID: 22960273
[TBL] [Abstract][Full Text] [Related]
19. Prognostic role and interaction of TERT promoter status, telomere length and MGMT promoter methylation in newly diagnosed IDH wild-type glioblastoma patients.
Giunco S; Padovan M; Angelini C; Cavallin F; Cerretti G; Morello M; Caccese M; Rizzo B; d'Avella D; Puppa AD; Chioffi F; De Bonis P; Zagonel V; De Rossi A; Lombardi G
ESMO Open; 2023 Jun; 8(3):101570. PubMed ID: 37230028
[TBL] [Abstract][Full Text] [Related]
20. [Analyses of IDH1 mutation and MGMT promoter methylation status for 5 cases of long-term survivors with glioblastoma].
Kamoshima Y; Motegi H; Terasaka S; Kobayashi H; Yamaguchi S; Murata J; Tanaka S; Houkin K
No Shinkei Geka; 2012 Feb; 40(2):129-35. PubMed ID: 22281465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
